Karo Bio: Year-End Report 2014

Regulatory News:

Karo Bio AB: (STO:KARO)

The full year 2014 and the fourth quarter in brief

• Net sales amounted to MSEK 30.1 (47.0), whereof the fourth quarter MSEK 8.1 (9.7)
• Net loss for the group was MSEK 59.3 (22.1), whereof the fourth quarter MSEK 21.8 (3.3)
• Loss per share was SEK 0.09 (0.04), whereof the fourth quarter SEK 0.03 (0.01)
• Cash flow from operating activities was MSEK -46.3 (-33.4), whereof the fourth quarter MSEK -10.7 (-7.9)
• Cash and cash equivalents and other short-term investments totaled MSEK 51.6 (22.8) at the end of the period
• The marketing company Karo Pharma was established during the fourth quarter
• Continued investment in the ERbeta cancer project for advancement towards the clinic
• Pfizer has taken over development of the RORgamma project, which means that the project has taken a step further into a new phase

Significant events after the end of the reporting period

• On February 4, Anders Lönner was appointed Executive Chairman of the Board and Maria Sjöberg CEO after Per Bengtsson

Conference call / audiocast today at 11.00 a.m. CET A presentation of the report (in Swedish) will take place today 11.00 a.m. The presentation and slides are available through the corporate website http://www.karobio.se/ or by telephone +468 566 426 94. Questions may be submitted over the internet or by telephone.

Karo Bio AB (publ) Novum 141 57 Huddinge Sweden Telephone: +46 8 608 60 00 Corp.reg.nr. 556309-3359 Website: www.karobio.com

The information in this report is such that Karo Bio is required to disclose under the Swedish Securities Market Act. The information was disclosed on February 13, 2015 at 8.30 a.m. CET.

This information was brought to you by Cision http://news.cision.com